Objective: To investigate the differences in clinicopathological and molecular characteristics between pure ovarian endometrioid carcinoma (POEC) and synchronous endometrial and ovarian endometrioid carcinoma (SEOEC), aiming to provide a basis for …
Mesonephric-like adenocarcinoma (MLA) is a rare gynecologic malignancy primarily arising in the uterine corpus and ovaries. It shares remarkable similarities in its histomorphology, immunophenotype, and molecular features with mesonephric adenocarcinoma …
Endometriosis is a benign yet chronic gynecological disorder characterized by dysregulation of processes such as inflammation, angiogenesis, migration, apoptosis, and proliferation. Menstrual blood-derived endometrial stem cells play a crucial role …
To explore the clinicopathological features and origin of mesonephric-like adenocarcinomas (MLAs), 83 cases diagnosed or suspected to be MLAs were collected from various institutions in Japan. We clearly classified 78 …
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times
FDA Approves Novel Treatment for KRAS-Mutated Ovarian Cancer Medscape
Endometriosis is one of the most common gynecological benign disease. Epidemiological evidence suggests a potential association between endometriosis and cancer risk. Accumulating evidence highlighted the risk of ovarian cancer, particularly …
The molecular mechanisms through which endometriosis-related ovarian neoplasms (ERONs) develop from benign endometrioma remain unclear. It is especially a long-standing mystery why ovarian endometrioma has the potential to develop into …
Endometriosis is a widely spread disease that affects about 8% of the world's female population. This condition may be described as a spread of endometrial tissue apart from the uterine …
Is there an association between the somatic loss of PTEN (phosphatase and tensin homolog) and ARID1A (AT-rich interaction domain 1A) and endometriosis disease severity and worse clinical outcomes?